Omeros Q3 net revenue rises 26% on YARTEMLEA sales
OMER•Omeros said third-quarter net revenue rose 26% sequentially on YARTEMLEA sales growth. The company reported a $57.4 million GAAP net loss and repurchased $30.5 million of its 2029 Notes.
1. Revenue and results
Omeros said third-quarter net revenue rose 26% sequentially, driven by YARTEMLEA sales growth. It reported a GAAP net loss of $57.4 million, or $0.79 per share, due to a non-cash loss on convertible notes, and reported non-GAAP adjusted net income.
2. Sales and outlook
The company said YARTEMLEA sales were supported by an expanded customer base, increased outpatient use, higher purchases by 340B entities, field education and new Medicare reimbursement advantages. It said revenues continued to grow into the fourth quarter and expects to initiate clinical studies for YARTEMLEA in ARDS and TA-TMA prevention in late 2026 or early 2027.
3. Notes and milestones
Omeros repurchased $30.5 million of its 2029 Notes, reducing interest obligations and potential share dilution. The company anticipates near-term milestone payments from Novo related to zaltenibart development.




